Table 1.
Summary and main characteristics of the FMT datasets included in this meta-analysis
| Disease | No. of datasets (new datasets) | No. of recipients (new recipients) | No. of samples (new samples) | Median no. of post-FMT samples [IQR] | Disease category | Countries |
|---|---|---|---|---|---|---|
| Clostridioides difficile infection | 9 (1) | 96 (16) | 529 (94) | 2.0 [3.0] | Infectious | Italy, Germany, Norway, USA, Canada |
| Inflammatory bowel disease | 5 (1) | 38 (2) | 188 (8) | 2.0 [1.0] | Chronic | France, Italy, USA |
| Multidrug-resistant bacteria colonization | 3 (1) | 21 (5) | 109 (13) | 1.0 [2.0] | Infectious | Italy, Israel, France, the Netherlands, Switzerland |
| Melanoma | 2 | 24 | 248 | 4 [7] | Oncological | Israel, USA |
| Tourette syndrome | 1 | 5 | 25 | 2.0 [0.0] | Chronic | China |
| Metabolic syndrome | 2 | 16 | 154 | 3 [0.2] | Chronic | the Netherlands |
| Irritable bowel syndrome | 1 | 20 | 91 | 2.0 [0.0] | Chronic | Norway |
| Tyrosine kinase inhibitor-dependent diarrhea | 1 | 6 | 27 | 2.0 [1.5] | Oncological | Italy |
| Total | 24 (3) | 226 (23) | 1,371 (116) | 2 [2] |
Numbers in parenthesis refer to data collected specifically for the present study.